The human CCL2 ELISA Kit quantitates human CCL2 levels in multiple samples, including serum, plasma, urine, saliva, cerebrospinal fluid (CSF), ascitic fluid, cell culture supernates, and tissue homogenates. CCL2, also called MCP-1, is inducibly expressed when exposed to inflammatory stimuli, such as IL-1, IL-4, IL-6, and TNFα. CCL2-CCR2 signaling activates several downstream signaling cascades, including JAK2/STAT3, MAPK, and PI3K pathways. CCL2-CCR2 interaction is involved in neurogenesis, neurotransmission, neuroinflammation, neurodegeneration, neuroregeneration, and other neurobiological processes. CCL2 is implicated in the pathogenesis of diseases, including congestive heart failure, multiple sclerosis, and atherosclerosis. Besides, CCL2 has been found in many types of cancer, such as breast, prostate, and pancreatic cancer, where CCL2 not only recruits immune cells to the tumor microenvironment but also acts on tumor cells to regulate angiogenesis, metastasis, and tumor cell proliferation.
This kit employs the sandwich-ELISA mechanism in conjugation with CCL2 antibody-CCL2 antigen-specific binding as well as HRP-TMB chromogenic reaction to measure the concentration of CCL2 in the samples. The kit is characterized by high sensitivity, strong specificity, good linearity, high recovery, and a precision of less than 10%.